Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Infectious Diseases

• Publication date

  2002-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1086/339015PMID 11865417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.

  2002cited by this paper
• Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy.

  2002cited by this paper
• Antibody Binding and Neutralization of Primary and T-Cell Line-Adapted Isolates of Human Immunodeficiency Virus Type 1

  2001cited by this paper
• Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.

  2001cited by this paper
• HIV-1 rebound after anti-retroviral therapy

  2000cited by this paper
• Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy

  2000cited by this paper
• Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.

  2000cited by this paper
• V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies

  2000cited by this paper
• Association of Structural Changes in the V2 and V3 Loops of the gp120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus Passaged In Vivo

  2000cited by this paper
• A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.

  1999cited by this paper
• AIDS: Re-emergence of HIV after stopping therapy

  1999cited by this paper
• Selection for Neutralization Resistance of the Simian/Human Immunodeficiency Virus SHIVSF33A Variant In Vivo by Virtue of Sequence Changes in the Extracellular Envelope Glycoprotein That Modify N-Linked Glycosylation

  1999cited by this paper
• CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization

  1998cited by this paper
• Mutations in both gp120 and gp41 Are Responsible for the Broad Neutralization Resistance of Variant Human Immunodeficiency Virus Type 1 MN to Antibodies Directed at V3 and Non-V3 Epitopes

  1998cited by this paper
• Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage

  1998cited by this paper
• Development of a Neutralizing Antibody Response during Acute Primary Human Immunodeficiency Virus Type 1 Infection and the Emergence of Antigenic Variants

  1998cited by this paper
• Human immunodeficiency virus type 1 intersubtype (B/E) recombination in a superinfected chimpanzee

  1997influential reference
• Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies

  1997cited by this paper
• Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

  1997cited by this paper
• Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off

  1997cited by this paper
• Antigenic variation of SIV: mutations in V4 alter the neutralization profile.

  1996cited by this paper
• TreeView: an application to display phylogenetic trees on personal computers

  1996cited by this paper
• Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites

  1996cited by this paper
• Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

  1996cited by this paper
• Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.

  1995cited by this paper
• Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120

  1995cited by this paper
• Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization

  1994cited by this paper
• Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120

  1993cited by this paper
• Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody

  1993cited by this paper
• Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys

  1993cited by this paper
• Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene

  1992cited by this paper
• Autologous HIV‐1 Neutralizing Antibodies: Emergence of Neutralization‐Resistant Escape Virus and Subsequent Development of Escape Virus Neutralizing Antibodies

  1992cited by this paper
• Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.

  1990cited by this paper
• Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

  1990cited by this paper
• Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees

  1990cited by this paper

• A die is cast: autologous neutralizing antibody resistance shapes the HIV reservoir during uninterrupted ART

  2025cites this paper
• Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies

  2025cites this paper
• Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption

  2023cites this paper
• Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates

  2022cites this paper
• Highly Efficient Neutralization by Plasma Antibodies from Human Immunodeficiency Virus Type-1 Infected Individuals on Antiretroviral Drug Therapy

  2014cites this paper
• Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.

  2010cites this paper
• Enhanced Exposure of Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Epitopes through Binding of CD4 Mimetic Compounds

  2010cites this paper
• 抗HIV中 和抗体 Anti-HIV Neutralizing Antibodies 柴田 潤二 , 松下 修三 *

  2010cites this paper
• CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease.

  2007cites this paper
• Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.

  2007influential citation
• Impact of V2 Mutations on Escape from a Potent Neutralizing Anti-V3 Monoclonal Antibody during In Vitro Selection of a Primary Human Immunodeficiency Virus Type 1 Isolate

  2007cites this paper
• Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors

  2006cites this paper
• HIV-1-Specific CD4+ T-Cell Responses Are Not Associated With Significant Viral Epitope Variation in Persons With Persistent Plasma Viremia

  2006cites this paper
• Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters

  2006cites this paper
• Effect of a Protease Inhibitor-Induced Genetic Bottleneck on Human Immunodeficiency Virus Type 1 env Gene Populations

  2005cites this paper
• Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247

  2005influential citation
• IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

  2005cites this paper
• The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1.

  2003cites this paper
• Antimicrobial agents: bacterial/fungal

  2002cites this paper
• HIV (1) -免疫応答によるHIV感染・増殖の制御-

  2002cites this paper